全文获取类型
收费全文 | 232篇 |
免费 | 41篇 |
国内免费 | 10篇 |
专业分类
儿科学 | 12篇 |
妇产科学 | 3篇 |
基础医学 | 4篇 |
临床医学 | 21篇 |
内科学 | 5篇 |
皮肤病学 | 2篇 |
神经病学 | 108篇 |
特种医学 | 2篇 |
外科学 | 3篇 |
综合类 | 11篇 |
预防医学 | 7篇 |
眼科学 | 1篇 |
药学 | 97篇 |
2篇 | |
中国医学 | 1篇 |
肿瘤学 | 4篇 |
出版年
2023年 | 9篇 |
2022年 | 17篇 |
2021年 | 14篇 |
2020年 | 20篇 |
2019年 | 7篇 |
2018年 | 13篇 |
2017年 | 15篇 |
2016年 | 8篇 |
2015年 | 15篇 |
2014年 | 9篇 |
2013年 | 35篇 |
2012年 | 13篇 |
2011年 | 22篇 |
2010年 | 7篇 |
2009年 | 11篇 |
2008年 | 18篇 |
2007年 | 14篇 |
2006年 | 13篇 |
2005年 | 10篇 |
2004年 | 4篇 |
2003年 | 6篇 |
2002年 | 2篇 |
2001年 | 1篇 |
排序方式: 共有283条查询结果,搜索用时 0 毫秒
1.
蒙天才 《中国继续医学教育》2020,(14):159-160
目的研究左乙拉西坦治疗小儿癫痫的疗效以及对智力的影响。方法在本院2017年4月-2019年5月收治的小儿癫痫患儿中选取74例开展研究,按照随机数表法分两组观察组和对照组,观察组37例,对照组37例,对照组采用奥卡西平进行治疗,观察组采用左乙拉西坦进行治疗,对比观察组与对照组组的治疗总有效率和智力评分变化。结果观察组与对照组比较,观察组的治疗总有效率较高,智力评分明显较高,两项对比差异有统计学意义(P <0.05)。结论左乙拉西坦治疗小儿癫痫有较好的治疗效果,治疗总有效率较高,且对患儿的智力有明显的改善作用,在实际临床小儿癫痫的治疗中具有较高的运用价值。 相似文献
2.
The purpose of this pilot single-site study was to assess efficacy and safety of levetiracetam for essential tremor, using a placebo-controlled, double-blind, randomized crossover design with an interim analysis planned after completion of the first 10 to 15 subjects. The study was designed to detect a mean 30% reduction in composite tremor score, comparable to that of primidone or propranolol, which can be demonstrated with 30 or fewer subjects. Each treatment arm included baseline tremor assessments, a 4-week medication titration, 2 weeks of stable dose, and treatment tremor assessments. Levetiracetam was titrated to 3,000 mg/day or to a lower maximal tolerated dose. The median age was 72 years, with 28 years median tremor duration. There was no statistically significant difference in response between placebo and levetiracetam on any tremor rating scale or accelerometry measure. The 95% confidence interval for the true mean difference between placebo and levetiracetam treatments was +18.5 to -22.5%, which excludes the minimum 30% drop required to consider levetiracetam clinically effective to a degree comparable to primidone or propranolol. Whether levetiracetam has lesser-degree antitremor efficacy was not addressed in this pilot study. 相似文献
3.
4.
V. Belcastro C. Costa F. Galletti F. Pisani P. Calabresi L. Parnetti 《European journal of neurology》2007,14(10):1176-1178
Levetiracetam (LEV) monotherapy was investigated in 25 patients with advanced Alzheimer's disease (AD) and new-onset epileptic seizures in a prospective open-label study. At a daily dose of 1000–1500 mg, 72% were seizure-free for at least one year; 16% discontinued for untolerability; 8% were unresponsive; 4% were lost to follow-up. These results suggest the need for controlled studies to confirm if LEV can be a first-choice drug in AD. 相似文献
5.
Bell C Vanderlinden H Hiersemenzel R Otoul C Nutt D Wilson S 《Journal of sleep research》2002,11(3):255-263
Levetiracetam is a novel antiepileptic drug which has recently been released as an adjunctive treatment for partial epilepsy. In the two studies reported here we examined the objective and subjective effects of levetiracetam on sleep in 12 healthy volunteers and 17 patients [16 who could be evaluated for electroencephalogram (EEG) recordings] with a history of partial epilepsy on stable carbamazepine monotherapy. The studies were of a similar double-blind crossover placebo-controlled design with subjects' sleep being recorded in their own homes. The results from the two studies showed considerable similarities. In both, levetiracetam produced an increase in the time spent in stage 2 sleep, which in the patient study was accompanied by a decrease in the time spent in stage 4 sleep and in the volunteer study an increase in rapid eye movement (REM) latency. The subjective changes included reports that sleep was of a better quality with fewer awakenings and patients also reported that their sleep was more restful. Volunteers and patients did, however, feel less alert on waking in the morning. Therefore, both groups reported a decrease in awakenings after levetiracetam despite the finding from the EEG of no change in the actual number of awakenings. It may be concluded from both studies that levetiracetam does affect some indicators of subjective sleep perception, but does not influence objective sleep measures of sleep continuity. The results from the patient study during placebo add-on treatment also showed that patients on carbamazepine had a marked increase in SWS, an increase in stage 2 sleep and an increase in REM latency compared with healthy volunteers. Interestingly, levetiracetam also reduced bilateral epileptiform EEG activity, particularly in patients with more discharges. 相似文献
6.
目的:探讨左乙拉西坦与苯巴比妥的药物相互作用及作用机制。方法:临床药师通过神经内科ICU的一例伴难以控制、反复发作癫的急性重症脑炎病例用药发现问题,查阅病历资料及相关文献进行分析。结果:左乙拉西坦可引起苯巴比妥血药浓度降低,可能与两者竞争结合P糖蛋白有关。结论:临床药师应该加强对左乙拉西坦的药物相互作用的观察和研究,以促进抗癫药物的合理应用。 相似文献
7.
Amy M. Spiegel Ming Teng Koh Nicholas M. Vogt Peter R. Rapp Michela Gallagher 《The Journal of comparative neurology》2013,521(15):3508-3523
Hippocampal interneuron populations are reportedly vulnerable to normal aging. The relationship between interneuron network integrity and age‐related memory impairment, however, has not been tested directly. That question was addressed in the present study using a well‐characterized model in which outbred, aged, male Long‐Evans rats exhibit a spectrum of individual differences in hippocampal‐dependent memory. Selected interneuron populations in the hippocampus were visualized for stereological quantification with a panel of immunocytochemical markers, including glutamic acid decarboxylase‐67 (GAD67), somatostatin, and neuropeptide Y. The overall pattern of results was that, although the numbers of GAD67‐ and somatostatin‐positive interneurons declined with age across multiple fields of the hippocampus, alterations specifically related to the cognitive outcome of aging were observed exclusively in the hilus of the dentate gyrus. Because the total number of NeuN‐immunoreactive hilar neurons was unaffected, the decline observed with other markers likely reflects a loss of target protein rather than neuron death. In support of that interpretation, treatment with the atypical antiepileptic levetiracetam at a low dose shown previously to improve behavioral performance fully restored hilar SOM expression in aged, memory‐impaired rats. Age‐related decreases in GAD67‐ and somatostatin‐immunoreactive neuron number beyond the hilus were regionally selective and spared the CA1 field of the hippocampus entirely. Together these findings confirm the vulnerability of hippocampal interneurons to normal aging and highlight that the integrity of a specific subpopulation in the hilus is coupled with age‐related memory impairment. J. Comp. Neurol. 521:3508‐3523, 2013. © 2013 Wiley Periodicals, Inc. 相似文献
8.
目的:建立同时测定人血浆中左乙拉西坦、奥卡西平及其代谢产物单羟基卡马西平的含量测定方法,为左乙拉西坦与奥卡西平联合用药治疗癫痫提高临床疗效与用药安全性提供指导。方法:患者血浆样品经乙酸乙酯-二氯甲烷(70:30)沉淀蛋白处理后,以β-萘酚做内标,采用RP-HPLC法同时测定左乙拉西坦、奥卡西平及单羟基卡马西平的含量。色谱柱为Agilent C18反相色谱柱,流动相为:乙腈(A)-水相(B)(由0.3%三氟乙酸与10 mmol·L-1甲酸铵溶液按2:1体积比混合)梯度洗脱,流速1 mL·min-1,柱温30℃,进样量10 μL,内标为β内萘酚,检测波长为210 nm (0~13 min)、225 nm (13~25 min)。结果:LEV、OXC、MHD血药浓度分别在2.0~60.0、2.0~60.0、3.0~96.0 μg·mL-1范围内线性关系良好(r分别为LEV 0.999 7、MHD 0.999 6、OXC 0.999 8),定量下限分别可达到2.0、2.0、3.0 μg·mL-1;各组分的日内、日间精密度RSD均小于4%,各方法平均回收率均大于96%,LEV、OXC、MHD低、中、高3个浓度的提取回收率均>85%,稳定性的RSD均<15%。结论:该方法操作简便、快捷,专属性强,结果准确可靠,可用于左乙拉西坦、奥卡西平及其代谢产物单羟基卡马西平的临床血药浓度监测。 相似文献
9.
10.